PMID- 32100146
OWN - NLM
STAT- MEDLINE
DCOM- 20210902
LR  - 20210902
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Print)
IS  - 0167-6997 (Linking)
VI  - 38
IP  - 5
DP  - 2020 Oct
TI  - Retrospective review of the activity and safety of apatinib and anlotinib in 
      patients with advanced osteosarcoma and soft tissue sarcoma.
PG  - 1559-1569
LID - 10.1007/s10637-020-00912-7 [doi]
AB  - Background Previous studies have demonstrated the efficacy of apatinib and 
      anlotinib for the treatment of sarcomas. However, more clinical data and evidence 
      are needed to support clinical treatment selection and study design. Here, we 
      evaluated the effectiveness and safety of these two drugs for the treatment of 
      sarcomas. Methods We retrospectively reviewed the data of 110 patients with 
      advanced osteosarcoma (n = 32) or soft tissue sarcoma (STS, n = 78) who received 
      oral apatinib or anlotinib therapy during May 2016-February 2019 at two centers. 
      Patients were divided into the apatinib and anlotinib groups. Results Among 
      osteosarcoma patients, the objective response rates (ORRs) for the apatinib and 
      anlotinib groups were 15.79% (3/19) and 7.69% (1/13), respectively. The disease 
      control rates (DCRs) were 63.16% (12/19) and 30.77% (4/13), and the median 
      progression-free survival (m-PFS) was 4.67 +/- 3.01 and 2.67 +/- 1.60 months, 
      respectively. Among STS patients, ORRs for the apatinib and anlotinib groups were 
      12.24% (6/49) and 13.79% (4/29), respectively. The DCRs were 59.18% (29/49) and 
      55.17% (16/29), and m-PFS was 7.82 +/- 6.90 and 6.03 +/- 4.50 months, respectively. 
      Regarding adverse events (AEs), apatinib was associated with a higher incidence 
      of hair hypopigmentation and pneumothorax, while anlotinib was associated with a 
      higher incidence of pharyngalgia or hoarseness. Conclusion Both apatinib and 
      anlotinib were effective for the treatment of sarcomas. However, the 
      effectiveness of the two drugs and associated AEs varied based on the 
      histological type of sarcoma. These differences may be due to their different 
      sensitivities to targets such as RET, warranting further study.
FAU - Tian, Zhichao
AU  - Tian Z
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China.
FAU - Liu, Huimin
AU  - Liu H
AD  - Department of Medical Oncology, The Affiliated People's Hospital of Zhengzhou 
      University, Zhengzhou, 450003, Henan Province, China.
FAU - Zhang, Fan
AU  - Zhang F
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China.
FAU - Li, Liangyu
AU  - Li L
AD  - Department of Orthopedics, the People's Hospital of Jiyuan, Jiyuan, 459000, Henan 
      Province, China.
FAU - Du, Xinhui
AU  - Du X
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China.
FAU - Li, Chao
AU  - Li C
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China.
FAU - Yang, Jinpo
AU  - Yang J
AD  - Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou 
      University and Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China.
FAU - Wang, Jiaqiang
AU  - Wang J
AUID- ORCID: 0000-0002-4978-1501
AD  - Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University 
      and Henan Cancer Hospital, Zhengzhou, 450008, Henan Province, China. 
      doctorwangjiaqiang@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200225
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Quinolines)
RN  - 0 (anlotinib)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Child
MH  - Female
MH  - Humans
MH  - Indoles/*administration & dosage/adverse effects
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Osteosarcoma/*drug therapy/mortality
MH  - Progression-Free Survival
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Pyridines/*administration & dosage/adverse effects
MH  - Quinolines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Sarcoma/*drug therapy/mortality
MH  - Soft Tissue Neoplasms/*drug therapy/mortality
MH  - Young Adult
PMC - PMC7497688
OTO - NOTNLM
OT  - Adverse events
OT  - Osteosarcoma
OT  - Pneumothorax
OT  - Soft tissue sarcoma
OT  - Tyrosine kinase inhibitor
COIS- All authors who took part in this study indicate that they do not have anything 
      to declare regarding funding or conflicts of interest with respect to this study.
EDAT- 2020/02/27 06:00
MHDA- 2021/09/03 06:00
PMCR- 2020/02/25
CRDT- 2020/02/27 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2020/02/12 00:00 [accepted]
PHST- 2020/02/27 06:00 [pubmed]
PHST- 2021/09/03 06:00 [medline]
PHST- 2020/02/27 06:00 [entrez]
PHST- 2020/02/25 00:00 [pmc-release]
AID - 10.1007/s10637-020-00912-7 [pii]
AID - 912 [pii]
AID - 10.1007/s10637-020-00912-7 [doi]
PST - ppublish
SO  - Invest New Drugs. 2020 Oct;38(5):1559-1569. doi: 10.1007/s10637-020-00912-7. Epub 
      2020 Feb 25.